• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

800毫克口服剂量后老年患者奥拉西坦的药代动力学,与非老年健康受试者的比较。

Pharmacokinetics of oxiracetam in elderly patients after 800 mg oral doses, comparison with non-geriatric healthy subjects.

作者信息

Lecaillon J B, Dubois J P, Coppens H, Darragon T, Theobald W, Reumond G, Beck H

机构信息

Biopharmaceutical Research Center and Medical Department, Laboratoires CIBA-GEIGY, Rueil-Malmaison, France.

出版信息

Eur J Drug Metab Pharmacokinet. 1990 Jul-Sep;15(3):223-30. doi: 10.1007/BF03190208.

DOI:10.1007/BF03190208
PMID:2253653
Abstract

The pharmacokinetics of oxiracetam have been studied in eighteen elderly patients and in six healthy non-geriatric adults. A 800 mg single oral dose was administered in the morning of the first day and repeatedly, every 12 h, from day 2 evening to day 10 morning, to the elderly patients. The healthy non-geriatric adults were given a 800 mg single oral dose of oxiracetam. In healthy non-geriatric subjects after a single oral administration of 800 mg, the normalized plasma levels of oxiracetam for 1 mg/kg dose were similar to those already recorded after a 2000 mg single dose of oxiracetam. Therefore, there was no tendency towards non-linear pharmacokinetics of oxiracetam between 800 and 2000 mg single doses in healthy subjects. After the single oral dose, the mean area under the plasma concentration-time curve of oxiracetam in elderly patients was increased by a factor of two as compared to that observed in non-geriatric healthy subjects whereas the maximum concentration (Cmax) was almost not modified and slightly delayed. This can be explained by a slower absorption and elimination in the elderly patients. The highest oxiracetam levels were predominantly recorded in the oldest patients. The slower elimination (mean T1/2 = 12.3 h in elderly and 7.7 h in healthy subjects) could be attributed to a physiological decrease of the renal function. The volume of distribution was not significantly modified in the elderly patients.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

已在18名老年患者和6名健康非老年成年人中研究了奥拉西坦的药代动力学。第一天上午给老年患者单次口服800毫克剂量,从第二天晚上到第十天上午,每12小时重复给药一次。给健康非老年成年人单次口服800毫克奥拉西坦。在健康非老年受试者单次口服800毫克后,每1毫克/千克剂量的奥拉西坦标准化血浆水平与单次口服2000毫克奥拉西坦后记录的水平相似。因此,在健康受试者中,800至2000毫克单次剂量之间奥拉西坦不存在非线性药代动力学趋势。单次口服给药后,老年患者奥拉西坦血浆浓度-时间曲线下的平均面积比非老年健康受试者增加了两倍,而最大浓度(Cmax)几乎未改变且略有延迟。这可以用老年患者吸收和消除较慢来解释。最高的奥拉西坦水平主要记录在年龄最大的患者中。消除较慢(老年患者平均T1/2 = 12.3小时,健康受试者为7.7小时)可能归因于肾功能的生理性下降。老年患者的分布容积没有明显改变。(摘要截短至250字)

相似文献

1
Pharmacokinetics of oxiracetam in elderly patients after 800 mg oral doses, comparison with non-geriatric healthy subjects.800毫克口服剂量后老年患者奥拉西坦的药代动力学,与非老年健康受试者的比较。
Eur J Drug Metab Pharmacokinet. 1990 Jul-Sep;15(3):223-30. doi: 10.1007/BF03190208.
2
Pharmacokinetics of oxiracetam in patients with renal impairment after a 800 mg single oral dose.单次口服800毫克后,奥拉西坦在肾功能损害患者中的药代动力学。
Eur J Drug Metab Pharmacokinet. 1990 Jul-Sep;15(3):231-7. doi: 10.1007/BF03190209.
3
Oxiracetam pharmacokinetics following single and multiple dose administration in the elderly.老年患者单次及多次给药后奥拉西坦的药代动力学
Eur J Drug Metab Pharmacokinet. 1987 Apr-Jun;12(2):145-8. doi: 10.1007/BF03189889.
4
Pharmacokinetic Properties of S-oxiracetam After Single and Multiple Intravenous Infusions in Healthy Volunteers.健康志愿者单次及多次静脉输注后 S-奥拉西坦的药代动力学特性
Eur J Drug Metab Pharmacokinet. 2021 Nov;46(6):793-805. doi: 10.1007/s13318-021-00718-9. Epub 2021 Sep 21.
5
Pharmacokinetic comparisons of S-oxiracetam and R-oxiracetam in beagle dogs.
Acta Pharm. 2016 Jun 1;66(2):279-87. doi: 10.1515/acph-2016-0013.
6
Pharmacokinetics of oxiracetam following intravenous and oral administration in healthy volunteers.奥拉西坦在健康志愿者体内静脉注射和口服给药后的药代动力学
Eur J Drug Metab Pharmacokinet. 1984 Jul-Sep;9(3):267-74. doi: 10.1007/BF03189650.
7
Simultaneous determination of oxiracetam and its degraded substance in rat plasma by HPLC-MS/MS and its application to pharmacokinetic study after a single high-dose intravenous administration.采用高效液相色谱-串联质谱法同时测定大鼠血浆中奥拉西坦及其降解产物,并将其应用于单次大剂量静脉给药后的药代动力学研究。
J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Oct 15;969:95-100. doi: 10.1016/j.jchromb.2014.07.041. Epub 2014 Aug 4.
8
Enantioselective HPLC determination of oxiracetam enantiomers and application to a pharmacokinetic study in beagle dogs.对映体选择性高效液相色谱法测定奥拉西坦对映体及其在比格犬体内的药代动力学研究中的应用。
J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Jul 1;993-994:9-13. doi: 10.1016/j.jchromb.2015.04.033. Epub 2015 Apr 30.
9
Comparative pharmacokinetic studies of racemic oxiracetam and its pure enantiomers after oral administration in rats by a stereoselective HPLC method.
J Pharm Biomed Anal. 2015;111:153-8. doi: 10.1016/j.jpba.2015.03.039. Epub 2015 Apr 4.
10
Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration.老年受试者中双重食欲素受体拮抗剂 ACT-541468 的临床药理学:单次晨服和多次晚服后的药代动力学、药效学和耐受性探索。
J Psychopharmacol. 2020 Mar;34(3):326-335. doi: 10.1177/0269881119882854. Epub 2019 Oct 23.

引用本文的文献

1
Pharmacokinetics of oxiracetam in patients with renal impairment after a 800 mg single oral dose.单次口服800毫克后,奥拉西坦在肾功能损害患者中的药代动力学。
Eur J Drug Metab Pharmacokinet. 1990 Jul-Sep;15(3):231-7. doi: 10.1007/BF03190209.
2
Absorption and disposition of 14C-labelled oxiracetam in rat, dog and man.14C标记的奥拉西坦在大鼠、狗和人体中的吸收与分布。
Eur J Drug Metab Pharmacokinet. 1992 Jan-Mar;17(1):67-82. doi: 10.1007/BF03189990.

本文引用的文献

1
An incremental method for the study of the absorption of drugs whose kinetics are described by a two-compartment model: estimation of the microscopic rate constants.
J Pharmacokinet Biopharm. 1983 Aug;11(4):401-24. doi: 10.1007/BF01058958.
2
Nomogram for estimating creatinine clearance.估算肌酐清除率的列线图。
Clin Pharmacokinet. 1983 Jul-Aug;8(4):365-9. doi: 10.2165/00003088-198308040-00007.
3
Pharmacokinetics of oxiracetam following intravenous and oral administration in healthy volunteers.奥拉西坦在健康志愿者体内静脉注射和口服给药后的药代动力学
Eur J Drug Metab Pharmacokinet. 1984 Jul-Sep;9(3):267-74. doi: 10.1007/BF03189650.
4
Oxiracetam pharmacokinetics following single and multiple dose administration in the elderly.老年患者单次及多次给药后奥拉西坦的药代动力学
Eur J Drug Metab Pharmacokinet. 1987 Apr-Jun;12(2):145-8. doi: 10.1007/BF03189889.
5
Clinical and neuropsychological study with oxiracetam versus placebo in patients with mild to moderate dementia.奥拉西坦与安慰剂治疗轻至中度痴呆患者的临床及神经心理学研究
J Neural Transm Suppl. 1987;24:293-8.
6
Determination of oxiracetam in plasma and urine by column-switching high-performance liquid chromatography.采用柱切换高效液相色谱法测定血浆和尿液中的奥拉西坦。
J Chromatogr. 1989 Dec 29;497:223-30. doi: 10.1016/0378-4347(89)80021-0.